Table 2 Baseline characteristics
Parameter | Dimension | Cohort A | Cohort B | Cohort C | Group comparison |
|---|---|---|---|---|---|
Seizure activity related parameter | |||||
Duration of epilepsy at inclusion in days | Geometric Mean (95% CI) | 642 (372–1110) | 556.6 (313–991) | 292.1 (93–915) | p = 0.3341 |
Mean ± SEM | 950 ± 183 | 755 ± 180 | 512 ± 193 | ||
Monthly seizure frequency (MSF) | Geometric Mean (95% CI) | 4.06 (2.93-5.61) | 3.73 (1.79-7.77) | 3.54 (2.45-5.10) | p = 0.6021 |
Monthly cluster day (MCD) | Geometric Mean (95% CI) | 0.62 (0.26-1.31) | 0.48 (0.10-1.37) | 0.51 (0.10-1.53) | p = 0.7321 |
Animals with cluster in baseline or history | m/n (%) | 14/16 (87.5%) | 6/11 (54.5%) | 6/7 (85.7%) | p = 0.1133 |
Animals with status in baseline or history | m/n (%) | 4/16 (25%) | 1/11 (9.1%) | 2/7 (28.6%) | p = 0.5093 |
Animals without cluster or status in baseline or history | m/n (%) | 2/16 (12.5%) | 5/11 (45.5%) | 1/7 (14.3%) | p = 0.1133 |
Medication related parameter | |||||
Dose of phenobarbital (A, B) or imepitoin (C) at inclusion in mg/kg per day | Mean ± SEM Range | 9.49 ± 0.59 5.0-13.2 | 8.16 ± 0.59 4.0-11.4 | 55.0 ± 4.30 40.0-76.0 | p = 0.1382 |
Frequency of dogs with KBr at inclusion | m/n (%) | 7/16 (43.8%) | 2/11 (18.2%) | 0/7 (0%) | p = 0.0693 p = 0.1664 |
Frequency of dogs with any 2ndpermanent antiepileptic at inclusion | m/n (%) | 9/16 (56.3%) | 3/11 (27.3%) | 0/7 (0%) | p = 0.0273 p = 0.1374 |
Frequency of dogs with levetiracetam pulse therapy in baseline | m/n (%) | 1/16 (6.3%) | 4/11 (36.4%) | 2/7 (28.6%) | p = 0.1383 p = 0.0484 |
Add-on dose of imepitoin (A, B) or phenobarbital (C) at inclusion (mg/kg per day) | Mean ± SEM Range | 23.5 ± 1.44 17.6-40.0 | 10.8 ± 0.47 8.6-14.8 | 1.2 ± 0.06 0.9-1.4 | |